Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Italy Fines Apple €98.6 Million Over App Store Dominance 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
WESTLAKE VILLAGE, Calif., Sept. 07, 2017 -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) announced today the company’s support for Hurricane Harvey victims with a donation of Afrezza® (insulin human) Inhalation Powder. The donation will be shipped this week to Insulin for Life USA, Inc., a not-for-profit entity whose purpose is to aid those living with diabetes by supplying life-saving insulin and other disease management supplies in times of need. Insulin for Life USA, Inc., The American Diabetes Association, and JDRF have partnered to ensure that donated diabetic supplies get to shelters and county health leaders in the affected areas as soon as possible.
“In times of crisis, many of us rely on our good health to help us get to better days,” said Michael Castagna, CEO of MannKind Corporation. “Among the millions of residents impacted by Hurricane Harvey are people who must manage their diabetes to maintain good health – but are separated by circumstance from their supplies. Extending a helping hand is consistent with our company’s values, and simply the right thing to do.”
Available through prescription only, Afrezza® is a rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. MannKind has authorized over 27,000 cartridges of insulin to be donated to Insulin for Life USA. For more information, including important safety information, on Afrezza®, visit www.afrezza.com.
“When it comes to rebuilding a life following a major event like Hurricane Harvey, things rarely go according to schedule,” said Castagna. “We hope that our support provides some relief to those in need during such a challenging time.”
About MannKind Corporation
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) inhalation powder, the Company's first FDA approved product, in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.
Company Contact: Rose Alinaya SVP, Investor Relations 818-661-5000 [email protected]
